Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration
Figure 3
Spectral domain OCT over time of a 67-year-old female previously treated with 30 ranibizumab injections. (a) OCT image 34 days after the last ranibizumab injection showing a primarily hyporeflective PED with a minimal amount of subretinal fluid. Note the complete disruption of the subfoveal IS/OS line. Visual acuity is 35 ETDRS letters (0.40 logMAR). (b) OCT image at month 1, after the first aflibercept injection, shows a decrease in PED height, almost complete resolution of the hyporeflective component of the PED, and a decrease in subretinal fluid. Visual acuity is unchanged. (c) OCT image at month 3, after three aflibercept injections, shows a complete resolution of the hyporeflective component of the PED while the hyperreflective component is almost unchanged. Visual acuity is 33 letters (0.44 logMAR). (d) OCT image at month 6 shows no significant anatomical changes as compared with (c). Visual acuity is 36 letters (0.38 logMAR).
